---
schema_version: "secwatch.filing_event.v1"
accession: "0001562762-22-000036"
form_type: "8-K"
ticker: "GMED"
cik: "0001237831"
company_name: "GLOBUS MEDICAL INC"
filed_at: "2022-02-17T23:59:59+00:00"
generated_at: "2026-06-27T06:55:20.432427+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Globus Medical Q4 sales $250M (+7.1% YoY); FY21 sales $958.1M (+21.4%); guides FY22 sales $1.025B

## Summary
- Q4 GAAP diluted EPS $0.14, non-GAAP $0.49; GAAP net income $15.1M down 71.5% due to IPR&D acquisition
- Full-year GAAP EPS $1.44, non-GAAP EPS $2.04; adjusted EBITDA $331.4M (34.6% of sales)
- Enabling Technology revenue Q4 $25M, FY $81M (+100% YoY); US Spine +18%, International +12%
- FY 2022 guidance: net sales $1.025B, non-GAAP diluted EPS $2.10; company remains debt-free
- Free cash flow for FY 2021 was $219.4M

## SEC filing metadata
- accession: 0001562762-22-000036
- form_type: 8-K
- ticker: GMED
- cik: 0001237831
- company_name: GLOBUS MEDICAL INC
- filed_at: 2022-02-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1237831/000156276222000036/0001562762-22-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1237831/000156276222000036/gmed-20220217x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001562762-22-000036
- JSON: https://secwatch.observer/filing/0001562762-22-000036.json
- Plain text: https://secwatch.observer/filing/0001562762-22-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.